期刊论文详细信息
BMC Cancer
Case–control study of HLA-G promoter methylation status, HPV infection and cervical neoplasia in Curitiba, Brazil: a pilot analysis
Anna Gillio-Tos2  Maria da Graça Bicalho5  Valentina Fiano2  Chiara Grasso2  Valentina Tarallo2  Laura De Marco2  Morena Trevisan2  MarinaBarbaradeSousa Xavier5  Renata Slowik5  Newton S Carvalho4  Carlos A Maestri3  Hadriano M Lacerda2  Daniela Zugna2  Lorenzo Richiardi1  Franco Merletti1 
[1] Centre for Oncologic Prevention, Turin, Italy
[2] Department of Medical Sciences, Unit of Cancer Epidemiology – C.E.R.M.S, University of Turin, Turin, Italy
[3] Department of Cervical Pathology, Hospital Erasto Gaertner, Curitiba, Brazil
[4] Department of Gynecology and Obstetrics, Federal University of Paraná, Infectious Diseases in Gynecology and Obstetrics Sector, Hospital de Clínicas, Curitiba, Brazil
[5] Laboratory of Immunogenetics and Hystocompatibility, Federal University of Paranà, Curitiba, Brazil
关键词: Methylation;    HLA-G;    Cervical cancer;    HPV;   
Others  :  1134861
DOI  :  10.1186/1471-2407-12-618
 received in 2012-07-10, accepted in 2012-12-13,  发布年份 2012
PDF
【 摘 要 】

Background

The causal association between persistent human papillomavirus (HPV) infection and cervical cancer has been established, but the mechanisms that favor HPV persistence in cervical cells are still unknown. The diminished capability of the immune system to control and resolve HPV infection is one of several hypotheses. The tolerogenic protein HLA-G has shown aberrant expression in a variety of cancers, which has been suggested as a mechanism for tumor escape from immunosurveillance. In the present study we evaluate the role of epigenetic modification (promoter de-methylation) of the HLA-G gene on susceptibility to HPV infection and development of high-grade cervical lesions.

Methods

A case–control study was carried out in Curitiba, Brazil, between February and June 2010. A total of 789 women aged 15–47 years were recruited: 510 controls with normal cervical cytology, and 279 cases with histologically confirmed cervical intraepithelial neoplasia grade 2 (CIN2, N = 150) or grade 3 (CIN3, N = 129). All women were administered a questionnaire by interview, which collected information on demographic and lifestyle factors, and a cervical sample was collected. HPV DNA detection was performed by GP5+/GP6+ primer-mediated PCR. HPV-positive samples were genotyped by multiplex PCR. A pilot analysis of HLA-G promoter methylation was carried out in a subset of the study population (96 cases and 76 controls) by pyrosequencing. HLA-G methylation and HPV infection status of cases and controls were compared, and confounding factors were computed by t Student and non-parametric Wilcoxon tests. Comparison of HLA-G methylation between cases and controls was assessed by the Bonferroni correction. The association of HLA-G methylation with CIN2/3 was evaluated by logistic regression.

Results

HPV prevalence was 19.6% in controls and 94.3% in CIN2/3 cases. HPV16, 31, 33, 35 and 18 were the most prevalent types. Methylation analysis of seven CpGs in the HLA-G promoter did not reveal any spontaneous de-methylation events in CIN2/3 cases (mean proportion of methylation: 75.8%) with respect to controls (mean 73.7%; odds ratio 1.01, 95% confidence interval 0.96, 1.07).

Conclusions

This study did not support the hypothesis that spontaneous de-methylation events in the HLA-G promoter play a primary role in promoting escape from immunosurveillance in the development of precancerous cervical lesions.

【 授权许可】

   
2012 Gillio-Tos et al.; licensee BioMed Central Ltd.

【 预 览 】
附件列表
Files Size Format View
20150306092307240.pdf 248KB PDF download
【 参考文献 】
  • [1]Globcan 2008: International Agency for Research on Cancer. [http://globocan.iarc.fr webcite]
  • [2]zur Hausen H: Papillomaviruses--to vaccination and beyond. Biochemistry 2008, 73:498-503.
  • [3]He X, Dong DD, Yie SM, Yang H, Cao M, Ye SR, Li K, Liu J, Chen J: HLA-G expression in human breast cancer: implications for diagnosis and prognosis, and effect on allocytotoxic lymphocyte response after hormone treatment in vitro. Ann Surg Oncol 2010, 17:1459-1469.
  • [4]Maki G, Hayes GM, Naji A, Tyler T, Carosella ED, Rouas-Freiss N, Gregory SA: NK resistance of tumor cells from multiple myeloma and chronic lymphocytic leukemia patients: implication of HLA-G. Leukemia 2008, 22:998-1006.
  • [5]Menier C, Rouas-Freiss N, Carosella ED: The HLA-G non-classical MHC class I molecule is expressed in cancer with poor prognosis. Implications in tumour escape from immune system and clinical applications. Atlas Genet Cytogenet Oncol Haematol 2009, 6:879-900.
  • [6]Jung YW, Kim YT, Kim SW, Kim S, Kim JH, Cho NH, Kim JW: Correlation of human leukocyte antigen-G (HLA-G) expression and disease progression in epithelial ovarian cancer. Reprod Sci 2009, 16:1103-1111.
  • [7]Le Maoult J, Zafaranloo K, Le Danff C, Carosella ED: HLA-G upregulates ILT2, ILT3, ILT4, and KIR2DL4 in antigen presenting cells, NK cells, and T cells. FASEB J 2005, 19:662-664.
  • [8]Clements CS, Kjer-Nielsen L, McCluskey J, Rossjohn J: Structural studies on HLA-G: implications for ligand and receptor binding. Hum Immunol 2007, 68:220-6.
  • [9]Hunt JS, Langat DL: HLA-G: a human pregnancy-related immunomodulator. Curr Opin Pharmacol 2009, 9:462-469.
  • [10]Kovats S, Main EK, Librach C, Stubblebine M, Fisher SJ, De Mars R: A class I antigen, HLA-G, expressed in human trophoblasts. Science 1990, 248:220-223.
  • [11]Crisa L, McMaster MT, Ishii JK, Fisher SJ, Salomon DR: Identification of a thymic epithelial cell subset sharing expression of the class Ib HLA-G molecule with fetal trophoblasts. J Exp Med 1997, 186:289-298.
  • [12]Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED: Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol 2003, 64:1039-1044.
  • [13]Cirulli V, Zalatan J, McMaster M, Prinsen R, Salomon DR, Ricordi C, Torbett BE, Meda P, Crisa L: The class I HLA repertoire of pancreatic islets comprises the nonclassical class Ib antigen HLA-G. Diabetes 2006, 55:1214-1222.
  • [14]Lajoie J, Fontaine J, Tremblay C, Routy JP, Poudrier J, Roger M: Persistence of high levels of blood soluble human leukocyte antigen-G is associated with rapid progression of HIV infection. AIDS 2009, 23:1437-1440.
  • [15]Dong DD, Yang H, Li K, Xu G, Song LH, Fan XL, Jiang XL, Yie SM: Human leukocyte antigen-G (HLA-G) expression in cervical lesions: association with cancer progression, HPV 16/18 infection, and host immune response. Reprod Sci 2010, 17:718-723.
  • [16]Deaton AM, Bird A: CpG islands and the regulation of transcription. Genes Dev 2011, 25:1010-1022.
  • [17]Menendez L, Walker LD, Matyunina LV, Totten KA, Benigno BB, McDonald JF: Epigenetic changes within the promoter region of the HLA-G gene in ovarian tumors. Mol Cancer 2008, 7:43.
  • [18]Ayres AR, Silva GA: Cervical HPV infection in Brazil: systematic review. Rev Saude Publica 2010, 44:963-974.
  • [19]Holanda F Jr, Castelo A, Veras TM, de Almeida FM, Lins MZ, Dores GB: Primary screening for cervical cancer through self sampling. Int J Gynaecol Obstet 2006, 95:179-184.
  • [20]Gakidou E, Nordhagen S, Obermeyer Z: Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med 2008, 5:e132.
  • [21]Giolo SR, Soler JMP, Greenway SC, Almeida MAA, de Andrade M, Seidman JG, Seidman CE, Krieger JE, Pereir AC: Brazilian urban population genetic structure reveals a high degree of admixture. Eur J Hum Genet 2012, 20:111-116.
  • [22]Dong SM, Pai SI, Rha SH, Hildesheim A, Kurman RJ, Schwartz PE, Mortel R, McGowan L, Greenberg MD, Barnes WA, Sidransky D: Detection and quantitation of human papillomavirus DNA in the plasma of patients with cervical carcinoma. Cancer Epidemiol Biomarkers Prev 2002, 11:3-6.
  • [23]van den Brule AJ, Pol R, Fransen-Daalmeijer N, Schouls LM, Meijer CJ, Snijders PJ: GP5+/6+ PCR followed by reverse line blot analysis enables rapid and high throughput identification of human papillomavirus genotypes. J Clin Microbiol 2002, 40:779-787.
  • [24]WHO/ICO: Human Papillomavirus and Related Cancers. 2010. [http://www.who.int/hpvcentre webcite]
  • [25]Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Menton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bültmann B: Detection and typing of human papillomavirus by e6 nested multiplex PCR. J Clin Microbiol 2004, 42:3176-3184.
  • [26]Yoshinouchi M, Hongo A, Nakamura K, Kodama J, Itoh S, Sakai H, Kudo T: Analysis by multiplex PCR of the physical status of human papillomavirus type 16 DNA in cervical cancers. J Clin Microbiol 1999, 37:3514-3517.
  • [27]Geraets DT, Heideman DA, de Koning MN, Snijders PJ, Meijer CJ, van Doorn LJ, Quint WG: High genotyping concordance between the Digene HPV Genotyping RH Test and the Reverse Line Blot genotyping assay on GP5+/6 + −PCR products. J Clin Virol 2009, 46(Suppl 3):S16-S20.
  • [28]Bouvard V, Baan R, Straif K, El Ghissassi F, Benbrahim-Tallaa L, Guha N, Freeman C, Galichet L, Gogliano V, on behalf of the WHO IARC in Cancer Monograph working group: A review of human carcinogens –Part B: biological agents. Lancet Oncol 2009, 10:321-322.
  • [29]Bansal N, Wright JD, Cohen CJ, Herzog TJ: Natural history of established low-grade cervical intraepithelial (CIN 1) lesions. Anticancer Res 2008, 28:1763-1766.
  • [30]Sastre-Garau X, Cartier I, Jourdan-Da Silva N, De Crémoux P, Lepage V, Charron D: Regression of low-grade cervical intraepithelial neoplasia in patients with HLA-DRB1*13 genotype. Obstet Gynecol 2004, 104:751-755.
  • [31]Cox JT, Schiffman M, Solomon D: Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 2003, 188:1406-1412.
  • [32]Melnikow J, Nuovo J, Willan AR, Chan BK, Howell LP: Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998, 92:727-735.
  • [33]Ostor AG: Natural history of cervical intraepithelial neoplasia: a critical review. IntJ Gynecol Pathol 1993, 12:186-192.
  • [34]Li XJ, Zhang X, Lin A, Ruan YY, Yan WH: Human leukocyte antigen-G (HLA-G) expression in cervical cancer lesions is associated with disease progression. Hum Immunol 2012, 73:946-949.
  • [35]Rodríguez JA, Galeano L, Palacios DM, Serrano ML, Bravo MM, Combita AL: Altered HLA Class I and HLA-G Expression Is Associated with IL-10 Expression in Patients with Cervical Cancer. Pathobiology 2012, 79:72-83.
  • [36]Zheng N, Wang CX, Zhang X, Du LT, Zhang J, Kan SF, Zhu CB, Dong ZG, Wang LL, Wang S, Li W: Up-regulation of HLA-G expression in cervical premalignant and malignant lesions. Tissue Antigens 2011, 77:218-224.
  • [37]Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG, Xie X: Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci 2006, 78:2643-2649.
  • [38]Poláková K, Russ G: Expression of the nonclassical HLA-G anti- gen in tumor cell lines is extremely restricted. Neoplasma 2000, 47:342-348.
  • [39]Amiot L, Ferrone S, Grosse-Wilde H, Seliger B: Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2011, 68:353-368.
  • [40]Carosella ED, Favier B, Rouas-Freiss N, Moreau P, LeMaoult J: Beyond the increasing complexity of the immunomodulatory HLA-G molecule. Blood 2008, 111:4862-4870.
  • [41]González-Bosquet E, Esteva C, Muñoz-Almagro C, Ferrer P, Pérez M, Lailla JM: Identification of vaccine human papillomavirus genotypes in squamous intraepithelial lesions (CIN2-3). Gynecol Oncol 2008, 111:9-12.
  • [42]Castle PE, Cox JT, Jeronimo J, Solomon D, Wheeler CM, Gravitt PE, Schiffman M: An analysis of high-risk human papillomavirus DNA-negative cervical precancers in the ASCUS-LSIL Triage Study (ALTS). Obstet Gynecol 2008, 111:847-856.
  • [43]Sigurdsson K, Taddeo FJ, Benediktsdottir KR, Olafsdottir K, Sigvaldason H, Oddsson K, Rafnar T: HPV genotypes in CIN 2–3 lesions and cervical cancer: a population-based study. Int J Cancer 2007, 121:2682-2687.
  • [44]Roteli-Martins CM, de Carvalho NS, Naud P, Teixeira J, Borba P, Derchain S, Tyring S, Gall S, Diaz A, Blatter M, Shier RM, Romanowski B, Quint WG, Issam J, Galindo C, Schuind A, Dubin G: Prevalence of human papillomavirus infection and associated risk factors in young women in Brazil, Canada, and the United States: a multicenter cross-sectional study. Int J Gynecol Pathol 2011, 30:173-184.
  • [45]Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, IARC HPV Prevalence Surveys Study Group: Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005, 366:991-998.
  • [46]Seliger B: Immune escape mechanisms of renal cell carcinoma. Eur Urol 2007, 6(Suppl 6):616-622.
  • [47]Seliger B, Schlaf G: Structure, expression and function of HLA-G in renal cell carcinoma. Semin Cancer Biol 2007, 17:444-450.
  • [48]Bukur J, Malenica B, Huber C, Seliger B: Altered expression of nonclassical HLA class 1B antigens in hu- man renal cell carcinoma and its association with impaired immune response. Hum Immunol 2003, 64:1081-1092.
  • [49]Rouas-Freiss N, Moreau P, Menier C, LeMaoult J, Carosella ED: Expression of tolerogenic HLA-G molecules in cancer prevents antitumor responses. Semin Cancer Biol 2007, 17:413-421.
  • [50]Rebmann V, Wagner S, Grosse-Wilde H: HLA-G expression in malignant melanoma. Semin Cancer Biol 2007, 17:422-429.
  • [51]Paul P, Rouas-Freiss N, Khalil-Daher I, Moreau P, Riteau B, Le Gal FA, Avril MF, Dausset J, Guillet JG, Carosella ED: HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci USA 1998, 95:4510-4515.
  • [52]Dong DD, Yie SM, Li K, Li F, Xu Y, Xu G, Song L, Yang H: Importance of HLA-G expression and tumor infiltrating lymphocytes in molecular subtypes of breast cancer. Hum Immunol 2012, 73:998-1004.
  • [53]Provatopoulou X, Kalogera E, Sagkriotis A, Zagouri F, Nonni A, Zografos GC, Gounaris A: Soluble human leukocyte antigen-G expression in patients with ductal and lobular breast malignancy. Anticancer Res 2012, 32:1021-1026.
  • [54]de Kruijf EM, Sajet A, van Nes JG, Natanov R, Putter H, Smit VT, Liefers GJ, van den Elsen PJ, van de Velde CJ, Kuppen PJ: HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J Immunol 2010, 185:7452-7459.
  • [55]Ye SR, Yang H, Li K, Dong DD, Lin XM, Yie SM: Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod Pathol 2007, 20:375-383.
  • [56]Zhu CB, Wang CX, Zhang X, Zhang J, Li W: Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int J Cancer 2011, 128:617-622.
  • [57]Cao M, Yie SM, Liu J, Ye SR, Xia D, Gao E: Plasma soluble HLA-G is a potential biomarker for diagnosis of colorectal, gastric, esophageal and lung cancer. Tissue Antigens 2011, 78:120-128.
  • [58]Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM: Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann Surg Oncol 2007, 14:2721-2729.
  • [59]Du L, Xiao X, Wang C, Zhang X, Zheng N, Wang L, Zhang X, Li W, Wang S, Dong Z: Human leukocyte antigen-G is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Sci 2011, 102:1272-1280.
  • [60]Ishigami S, Natsugoe S, Miyazono F, Nakajo A, Tokuda K, Matsumoto M, Okumura H, Douchi T, Hokita S, Aikou T: HLA-G expression in gastric cancer. Anticancer Res 2006, 26:2467-2472.
  • [61]Lin A, Zhang X, Zhou WJ, Ruan YY, Xu DP, Wang Q, Yan WH: Human leukocyte antigen-G expression is associated with a poor prognosis in patients with esophageal squamous cell carcinoma. Int J Cancer 2011, 129:1382-1390.
  • [62]Yie SM, Yang H, Ye SE, Li K, Dong DD, Lin XM: Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am J Clin Pathol 2007, 128:1002-1009.
  • [63]Schütt P, Schütt B, Switala M, Bauer S, Stamatis G, Opalka B, Eberhardt W, Schuler M, Horn PA, Rebmann V: Prognostic relevance of soluble human leukocyte antigen-G and total human leukocyte antigen class I molecules in lung cancer patients. Hum Immunol 2010, 71:489-495.
  • [64]Yie SM, Yang H, Ye SR, Li K, Dong DD, Lin XM: Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007, 58:267-274.
  • [65]Claus R, Lucas DM, Stilgenbauer S, Ruppert AS, Yu L, Zucknick M, Mertens D, Bühler A, Oakes CC, Larson RA, Kay NE, Jelinek DF, Kipps TJ, Rassenti LZ, Gribben JG, Döhner H, Heerema NA, Marcucci G, Plass C, Byrd JC: Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia. J Clin Oncol 2012, 30:2483-2491.
  • [66]Szalmás A, Kónya J: Epigenetic alterations in cervical carcinogenesis. Semin Cancer Biol 2009, 19:144-152.
  • [67]Burgers WA, Blanchon L, Pradhan S, de Launoit Y, Kouzarides T, Fuks F: Viral oncoproteins target the DNA methyltransferases. Oncogene 2007, 26:1650-1655.
  • [68]Wentzensen N, Sherman ME, Schiffman M, Wang SS: Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol Oncol 2009, 112:293-299.
  • [69]Polakova K, Bandzuchova E, Tirpakova J, Kuba D, Russ G: Modulation of HLA-G expression. Neoplasma 2007, 54:455-462.
  • [70]Castelli EC, Mendes-Junior CT, Veiga-Castelli LC, Roger M, Moreau P, Donadi EA: A comprehensive study of polymorphic sites along the HLA-G gene: implication for gene regulation and evolution. Mol Biol Evol 2011, 28:3069-3086.
  • [71]Veit TD, Chies JA: Tolerance versus immune response – microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol 2009, 20:229-231.
  • [72]Wiley KL, Treadwell E, Manigaba K, Word B, Lyn-Cook BD: Ethnic Differences in DNA Methyltransferases Expression in Patients with Systemic Lupus Erythematosus. J Clin Immunol 2012,  : . Epub October 9
  文献评价指标  
  下载次数:15次 浏览次数:6次